2024-02-12 19:11:56 ET
Summary
- Verve Therapeutics aims to revolutionize cardiovascular disease treatment with gene therapy.
- Recent VERVE-101 data shows LDL-C reduction comparable to existing drugs but with serious adverse events in two patients, raising safety concerns.
- Verve's financials show a solid runway with ~$600 million in liquid assets after a recent capital infusion, but ongoing and future trials will demand substantial funding.
- Recommendation: Sell. Despite proof-of-concept and a one-time treatment appeal, safety concerns and competitive landscape challenge its long-term valuation.
Verve's Genetic Play: Rewriting the Script on Cholesterol
Verve Therapeutics ( VERV ) has set out to change the way we treat cardiovascular disease. ...
Read the full article on Seeking Alpha
For further details see:
Verve's Proof-Of-Concept Data Doesn't Inspire Confidence